Late Friday Atlanta-based Alimera Sciences Inc. received the green light from the FDA for its Iluvien implant, indicated for diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.